Characteristics of and Treatment Strategies for Advanced EGFR-Mutant NSCLC With Concomitant BRAF Variations

Characteristics of and Treatment Strategies for Advanced EGFR-Mutant NSCLC With Concomitant BRAF Variations

Introduction: BRAF variants were reported resistant mechanisms to EGFR tyrosine kinase inhibitors (TKIs) in EGFR-mutant NSCLC. Nevertheless, characteristics and subsequent treatment strategies of such patients remain unclear. Methods: From October 2016 to May 2020, patients with advanced NSCLC for w...

Full description

Bibliographic Details
Main Authors: Chen, Z.-H (Author), Deng, J.-Y (Author), Wei, X.-W (Author), Wu, Q. (Author), Wu, Y.-L (Author), Xu, C.-R (Author), Zhang, X.-C (Author), Zhou, Q. (Author), Zhu, D.-Q (Author)
Format: Article
Language:English
Published: Elsevier Inc. 2022
Subjects:
BRAF
Characteristics
EGFR
NSCLC
Treatment strategy
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items